Sol­id Bio’s long, trou­bled slog through the clin­ic yields 'en­cour­ag­ing' ear­ly da­ta and no new safe­ty con­cerns. It's not win­ning over in­vestors yet

Those who have been fol­low­ing the gene ther­a­py space would be fa­mil­iar with Sol­id Bio’s IG­NITE-DMD tri­al. Be­set with safe­ty is­sues, the Phase I/II study was held down by clin­i­cal holds for the bet­ter part of the last three years, while the Duchenne-fo­cused biotech watched big­ger ri­vals dash by to­ward piv­otal work.

There was just one thing that we’ve nev­er seen: da­ta from the study on how pa­tients are do­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER